Price T Rowe Associates Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Price T Rowe Associates Inc

  • $836 Billion
  • Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 53,401 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,401
Previous 335,357 84.08%
Holding current value
$0
Previous $14.2 Million 84.59%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$38.96 - $42.75 $11 Million - $12.1 Million
-281,956 Reduced 84.08%
53,401 $2.18 Million
Q1 2024

May 15, 2024
SELL
$40.88 - $43.27 $15.8 Million - $16.7 Million
-385,698 Reduced 53.49%
335,357 $14.2 Million
Q4 2023

Feb 14, 2024
SELL
$20.27 - $42.44 $96.9 Million - $203 Million
-4,782,443 Reduced 86.9%
721,055 $30.6 Million
Q3 2023

Nov 14, 2023
BUY
$20.26 - $31.91 $5.65 Million - $8.89 Million
278,698 Added 5.33%
5,503,498 $120 Million
Q2 2023

Aug 14, 2023
BUY
$23.9 - $35.38 $10.2 Million - $15 Million
425,093 Added 8.86%
5,224,800 $166 Million
Q1 2023

May 15, 2023
SELL
$22.82 - $35.32 $111,521 - $172,608
-4,887 Reduced 0.1%
4,799,707 $117 Million
Q4 2022

Feb 14, 2023
BUY
$25.35 - $31.96 $900,432 - $1.14 Million
35,520 Added 0.74%
4,804,594 $152 Million
Q3 2022

Nov 14, 2022
SELL
$25.5 - $41.42 $38.9 Million - $63.2 Million
-1,526,834 Reduced 24.25%
4,769,074 $135 Million
Q2 2022

Aug 15, 2022
SELL
$20.62 - $37.15 $3.75 Million - $6.77 Million
-182,102 Reduced 2.81%
6,295,908 $166 Million
Q1 2022

May 16, 2022
BUY
$23.5 - $35.38 $11.2 Million - $16.9 Million
477,088 Added 7.95%
6,478,010 $227 Million
Q4 2021

Feb 14, 2022
BUY
$29.21 - $44.64 $4.68 Million - $7.15 Million
160,191 Added 2.74%
6,000,922 $195 Million
Q3 2021

Nov 15, 2021
BUY
$21.26 - $38.85 $53.4 Million - $97.6 Million
2,513,320 Added 75.53%
5,840,731 $172 Million
Q2 2021

Aug 16, 2021
SELL
$12.56 - $29.69 $910,311 - $2.15 Million
-72,477 Reduced 2.13%
3,327,411 $85.2 Million
Q1 2021

May 17, 2021
BUY
$12.37 - $17.74 $95,929 - $137,573
7,755 Added 0.23%
3,399,888 $46.7 Million
Q4 2020

Feb 16, 2021
BUY
$9.82 - $18.27 $33.3 Million - $62 Million
3,392,133 New
3,392,133 $54 Million

Others Institutions Holding CERE

# of Institutions
270
Shares Held
155M
Call Options Held
2.19M
Put Options Held
3.92M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email